GLP-2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet

Journal of Cellular Physiology

Volumn 230, Issue 12, 2015, Pages 3029-3036

  Baldassano, Sara ^a   Rappa, Francesca ^a,b   Amato, Antonella ^a   Cappello, Francesco ^a,b   Mulè, Flavia ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto Euro Mediterraneo di Scienza e Tecnologia (IEMEST)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 3 33; GLUCOSE; INSULIN; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUCAGON-LIKE PEPTIDE-2 (3-33); GLUCOSE BLOOD LEVEL; HORMONE ANTAGONIST; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CONTROLLED STUDY; DIET RESTRICTION; DIGESTIVE TRACT PARAMETERS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LONG TERM CARE; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PANCREAS; PANCREAS ISLET BETA CELL; PANCREAS WEIGHT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; METABOLISM; PATHOLOGY; TIME;

ANIMALIA; MUS;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; HORMONE ANTAGONISTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84939789285     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25039     Document Type: Article

References (55)

1. Ahrén B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F. 1997. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97-106.
2. Amato A, Baldassano S, Serio R, Mule' F. 2009. Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrointest Liver Physiol 296:G678-G684.
3. Amato A, Rotondo A, Cinci L, Baldassano S, Vannucchi MG, Mule' F. 2010. Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon. Am J Physiol Gastrointest Liver Physiol 299:G1038-G1044.
4. Asrih M, Jornayvaz FR. 2013. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 218:R25-R36.
5. Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ. 2010. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 139:857-868.
6. Baldassano S, Amato A. 2014. GLP-2: What do we know? What are we going to discover?. Regul Pept 194:6-10.
7. Baldassano S, Amato A, Cappello F, Rappa F, Mulè F. 2013. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J Endocrinol 217:11-20.
8. Baldassano S, Bellanca AL, Serio R, Mulè F. 2012. Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. J Endocrinol 213:277-284.
9. Baldassano S, Liu S, Qu MH, Mule' F, Wood JD. 2009. Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver Physiol 297:G800-G805.
10. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. 2000. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112-119.
11. Buettner R, Schölmerich J, Bollheimer LC. 2007. High-fat diets: Modeling the metabolic disorders of human obesity in rodents. Obesity 15:798-808.
12. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. 2007. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761-1772.
13. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. 2009. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:1091-1103.
14. Cheeseman CI. 1997. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. AJP 273:R1965-R1971.
15. Cinci L, Faussone-Pellegrini MS, Rotondo A, Mulè F, Vannucchi MG. 2011. GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility. Neurogastroenterol Motil 23:e383-e392.
16. 2+ channels from secretory vesicles. Diabetes 59:1192-1201.
17. Collins S, Martin TL, Surwit RS, Robidoux J. 2004. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81:243-248.
18. de Heer J, Pedersen J, Orskov C, Holst JJ. 2007. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50:2135-2142.
19. de Meijer VE, Le HD, Meisel JA, Akhavan Sharif MR, Pan A, Nosé V, Puder M. 2010. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism 59:1092-1105.
20. Drucker DJ, Yusta B. 2014. Physiology and Pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol 76:561-583.
21. El-Jamal N, Erdual E, Neunlist M, Koriche D, Dubuquoy C, Maggiotto F, Chevalier J, Berrebi D, Dubuquoy L, Boulanger E, Cortot A, Desreumaux P. 2014. Glugacon-like peptide-2: Broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am J Physiol Gastrointest Liver Physiol 307:G274-G285.
22. Flier SN, Kulkarni RN, Kahn CR. 2001. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci USA 98:7475-7480.
23. Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. 2010. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat iet. J Clin Biochem Nutr 46:212-223.
24. Guan X. 2014. The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis. Am J Physiol Regul Integr Comp Physiol 307:R585-R596.
25. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. 2006. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130:150-164.
26. Holst JJ. 2004. On the physiology of GIP and GLP-1. Horm Metab Res 36:747-754.
27. Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444:860-867.
28. Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL. 2009. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 150:4033-4043.
29. Janssen P, Rotondo A, Mulé F, Tack J. 2013. Review article: A comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther 37:18-36.
30. Jetton TL, Everill B, Lausier J, Roskens V, Habibovic A, LaRock K, Gokin A, Peshavaria M, Leahy JL. 2008. Enhanced beta-cell mass without increased proliferation following chronic mild glucose infusion. Am J Physiol Endocrinol Metab 294:E679-E687.
31. Jetton TL, Lausier J, LaRock K, Trotman WE, Larmie B, Habibovic A, Peshavaria M, Leahy JL. 2005. Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes 54:2294-2304.
32. Lamont BJ, Drucker DJ. 2008. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat-fed mice. Diabetes 57:190-198.
33. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE. 1995. Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11:206-211.
34. Levitt HE, Cyphert TJ, Pascoe JL, Hollern DA, Abraham N, Lundell RJ, Rosa T, Romano LC, Zou B, O'Donnell CP, Stewart AF, Garcia-Ocaña A, Alonso LC. 2011. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia 54:572-582.
35. Li HQ, Wang BP, Deng XL, Zhang JY, Wang YB, Zheng J, Xia WF, Zeng TS, Chen LL. 2011. Insulin improves β-cell function in glucose-intolerant rat models induced by feeding a high-fat diet. Metabolism 60:1566-1574.
36. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ. 2004. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in culture hippocampal cells. Endocrinology 145:3495-3506.
37. Marathe CS, Rayner CK, Jones KL, Horowitz M. 2013. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 44:75-86.
38. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. 2004. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 39:353-358.
39. Nelson DW, Murali SG, Liu X, Koopmann MC, Holst JJ, Ney DM. 2008. Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 294:R1175-R1184.
40. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM. 2007. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148:1954-1962.
41. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. 2005. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124:105-112.
42. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS. 1998. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 47:1089-1096.
43. Reimer MK1, Holst JJ, Ahrén B. 2002. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727.
44. Rotondo A, Amato A, Baldassano S, Lentini L, Mulè F. 2011. Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted. Peptides 32:1587-1592.
45. Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML, Stylopoulos N. 2013. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 341:406-410.
46. Shan CY, Yang JH, Kong Y, Wang XY, Zheng MY, Xu YG, Wang Y, Ren HZ, Chang BC, Chen LM. 2013. Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats. J Endocrinol 218:255-262.
47. Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, Li D, Burrin DG, Chan L, Guan X. 2013. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 18:86-98.
48. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. 2005. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128:1340-1353.
49. Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, Son HY. 2013. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig 4:334-343.
50. Stamateris RE, Sharma RB, Hollern DA, Alonso LC. 2013. Adaptive β-cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression. Am J Physiol Endocrinol Metab 305:E149-E159.
51. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. 1988. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167.
52. Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. 2000. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802-807.
53. Winzell MS, Magnusson C, Ahrén B. 2007. Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice. Metabolism 56:122-128.
54. Wøjdemann M, Wettergren A, Hartmann B, Holst JJ. 1998. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33:828-832.
55. Wu Y, Wu T, Wu J, Zhao L, Li Q, Varghese Z, Moorhead JF, Powis SH, Chen Y, Ruan XZ. 2013. Chronic inflammation exacerbates glucose metabolism disorders in C57BL/6J mice fed with high-fat diet. J Endocrinol 219:195-204.